An update of the global burden of pertussis in children younger than 5 years: a modelling study

Yeung, Karene Hoi Ting; Duclos, Philippe; Nelson, E. Anthony S.; Hutubessy, Raymond

doi:10.1016/s1473-3099(17)30390-0

Cited by 334 publications

(251 citation statements)

References 11 publications

Supporting

Mentioning

238

Contrasting

Unclassified

Order By: Relevance

“…Pertussis affects nearly 24 million children under the age of 5 years each year and causes 160 000 deaths in this age group 45. Peak incidence is seen in infants up to 6 months of age 6.…”

Section: How Common Is It?mentioning

confidence: 99%

Pertussis (whooping cough)

Gopal

Barber

Toeg³

2019

BMJ

View full text Add to dashboard Cite

“…Pertussis affects nearly 24 million children under the age of 5 years each year and causes 160 000 deaths in this age group 45. Peak incidence is seen in infants up to 6 months of age 6.…”

Section: How Common Is It?mentioning

confidence: 99%

Pertussis (whooping cough)

Gopal

Barber

Toeg³

2019

BMJ

View full text Add to dashboard Cite

“…Pertussis is a highly contagious respiratory disease caused primarily by the infection of a Gram‐negative bacterium Bordetella pertussis ( B. pertussis ) . However, despite the availability of vaccines such as the acellular vaccines (aPVs), 24.1 million infections and 160 700 deaths have been estimated worldwide in children younger than 5 years alone each year due to pertussis . Even in developed countries such as US and Australia where the vaccination rates are high, the number of reported cases of pertussis has markedly risen during recent decades, reaching a 60 year high .…”

Section: Introductionmentioning

confidence: 99%

Chemical Synthesis and Immunological Evaluation of a Pentasaccharide Bearing Multiple Rare Sugars as a Potential Anti‐pertussis Vaccine

et al. 2020

View full text Add to dashboard Cite

With the infection rate of Bordetella pertussis at a 60‐year high, there is an urgent need for new anti‐pertussis vaccines. The lipopolysaccharide (LPS) of B. pertussis is an attractive antigen for vaccine development. With the presence of multiple rare sugars and unusual glycosyl linkages, the B. pertussis LPS is a highly challenging synthetic target. In this work, aided by molecular dynamics simulation and modeling, a pertussis‐LPS‐like pentasaccharide was chemically synthesized for the first time. The pentasaccharide was conjugated with a powerful carrier, bacteriophage Qβ, as a vaccine candidate. Immunization of mice with the conjugate induced robust anti‐glycan IgG responses with IgG titers reaching several million enzyme‐linked immunosorbent assay (ELISA) units. The antibodies generated were long lasting and boostable and could recognize multiple clinical strains of B. pertussis, highlighting the potential of Qβ‐glycan as a new anti‐pertussis vaccine.

show abstract

“…The human-specific pathogen Bordetella pertussis causes pertussis, known commonly as whooping cough due to the telltale gasps that often follow intense coughing fits (Kline et al, 2013;Kilgore et al, 2016). An estimated 24 million children contract pertussis annually, resulting in 160,000 fatalities (Yeung et al, 2017). It is unclear whether antibiotic treatment is effective at reducing the severity or length of pertussis, and despite high vaccination rates, pertussis is reemerging in developed nations (Wang et al, 2014;WHO, 2014).…”

Section: Introductionmentioning

confidence: 99%

Regulated, sequential processing by multiple proteases is required for proper maturation and release of Bordetella filamentous hemagglutinin

Nash

Cotter

2019

Molecular Microbiology

View full text Add to dashboard Cite

Summary Filamentous hemagglutinin (FHA) is a critically important virulence factor produced by Bordetella species that cause respiratory infections in humans and other animals. It is also a prototypical member of the widespread two partner secretion (TPS) pathway family of proteins. First synthesized as a ~370 kDa protein called FhaB, its C‐terminal ~1,200 amino acid ‘prodomain’ is removed during translocation to the cell surface via the outer membrane channel FhaC. Here, we identify CtpA as a periplasmic protease that is responsible for the regulated degradation of the prodomain and for creation of an intermediate polypeptide that is cleaved by the autotransporter protease SphB1 to generate FHA. We show that the central prodomain region is required to initiate degradation of the prodomain and that CtpA degrades the prodomain after a third, unidentified protease (P3) first removes the extreme C‐terminus of the prodomain. Stepwise proteolysis by P3, CtpA and SphB1 is required for maturation of FhaB, release of FHA into the extracellular milieu, and full function in vivo. These data support a substantially updated model for the mechanism of secretion, maturation and function of this model TPS protein.

show abstract

An update of the global burden of pertussis in children younger than 5 years: a modelling study

Cited by 334 publications

References 11 publications

Pertussis (whooping cough)

Pertussis (whooping cough)

Chemical Synthesis and Immunological Evaluation of a Pentasaccharide Bearing Multiple Rare Sugars as a Potential Anti‐pertussis Vaccine

Regulated, sequential processing by multiple proteases is required for proper maturation and release of Bordetella filamentous hemagglutinin

Contact Info

Product

Resources

About